News

Video

Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia and the T315I Mutation: 4-Year Results From OPTIC

Author(s):

Jorge Cortes, MD

Jorge Cortes, MD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Jean L. Koff, MD, MS
Sonali M. Smith, MD
Naval G. Daver, MD,
Andrew Hantel, MD
Naval G. Daver, MD
A panel of 3 experts on ALL
Related Content
William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Leonard Mazur, CEO, Citius Pharma, Citius Oncology
September 6th 2024

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Reid W. Merryman, MD
September 5th 2024

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

Rayne Helen Rouce, MD, BS, Baylor College of Medicine
September 4th 2024

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL